发布求助
文献互助 智能选刊 最新文献

Cancer journal最新文献

筛选
英文 中文
Local Excision for Early-Stage Rectal Adenocarcinomas. 早期直肠腺癌的局部切除术
IF 2.6 4区 医学
Cancer journal Pub Date : 2024-07-01 DOI: 10.1097/PPO.0000000000000734
Kristen Donohue, Alexander Rossi, Matthew P Deek, Daniel Feingold, Nell Maloney Patel, Salma K Jabbour
{"title":"Local Excision for Early-Stage Rectal Adenocarcinomas.","authors":"Kristen Donohue, Alexander Rossi, Matthew P Deek, Daniel Feingold, Nell Maloney Patel, Salma K Jabbour","doi":"10.1097/PPO.0000000000000734","DOIUrl":"https://doi.org/10.1097/PPO.0000000000000734","url":null,"abstract":"<p><strong>Abstract: </strong>Although total mesorectal excision (TME) remains the standard of care for rectal cancer, including early-stage T1/T2 rectal adenocarcinoma, local excision may be warranted for these early-stage tumors in a select group of patients who may decline surgery or may be nonoptimal surgical candidates. Operative approaches for transanal local excision include transanal endoscopic microsurgery or transanal minimally invasive surgery for tumors <4 cm, occupying <40% of the rectal circumference and <10 cm from the dentate line. The use of preoperative chemoradiation therapy may help to downstage tumors and allow for more limited resections, and chemoradiation may also be employed postoperatively. Local excision approaches appear to result in improved quality of life compared with TME, but limited resections may also compromise survival rates compared with TME. Multidisciplinary management and shared decision-making can allow for the desired patient outcomes.</p>","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":"30 4","pages":"245-250"},"PeriodicalIF":2.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141751204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nonoperative Management for Rectal Cancer. 直肠癌的非手术疗法
IF 2.6 4区 医学
Cancer journal Pub Date : 2024-07-01 DOI: 10.1097/PPO.0000000000000727
Erqi L Pollom, Vipul R Sheth, Aaron J Dawes, Thomas Holden
{"title":"Nonoperative Management for Rectal Cancer.","authors":"Erqi L Pollom, Vipul R Sheth, Aaron J Dawes, Thomas Holden","doi":"10.1097/PPO.0000000000000727","DOIUrl":"10.1097/PPO.0000000000000727","url":null,"abstract":"<p><strong>Abstract: </strong>The treatment paradigm for rectal cancer has been shifting toward de-escalated approaches to preserve patient quality of life. Historically, the standard treatment in the United States for locally advanced rectal cancer has standardly comprised preoperative chemoradiotherapy coupled with total mesorectal excision. Recent data challenge this \"one-size-fits-all\" strategy, supporting the possibility of omitting surgery for certain patients who achieve a clinical complete response to neoadjuvant therapy. Consequently, patients and their physicians must navigate diverse neoadjuvant options, often in the context of pursuing organ preservation. Total neoadjuvant therapy, involving the administration of all chemotherapy and radiation before total mesorectal excision, is associated with the highest rates of clinical complete response. However, questions persist regarding the optimal sequencing of radiation and chemotherapy and the choice between short-course and long-course radiation. Additionally, meticulous response assessment and surveillance are critical for selecting patients for nonoperative management without compromising the excellent cure rates associated with trimodality therapy. As nonoperative management becomes increasingly recognized as a standard-of-care treatment option for patients with rectal cancer, ongoing research in patient selection and monitoring as well as patient-reported outcomes is critical to guide personalized rectal cancer management within a patient-centered framework.</p>","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":"30 4","pages":"238-244"},"PeriodicalIF":2.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11486344/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141751141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Local Therapy for Metastatic Colorectal Cancer: A Case-Based Review. 转移性结直肠癌的局部治疗：基于病例的综述。
IF 2.6 4区 医学
Cancer journal Pub Date : 2024-07-01 DOI: 10.1097/PPO.0000000000000730
Michael P Dykstra, Smith Apisarnthanarax, George Poultsides, Katelyn M Atkins, David Binder, Jeffrey Olsen, Dayssy Alexandra Diaz, Daniel T Chang
{"title":"Local Therapy for Metastatic Colorectal Cancer: A Case-Based Review.","authors":"Michael P Dykstra, Smith Apisarnthanarax, George Poultsides, Katelyn M Atkins, David Binder, Jeffrey Olsen, Dayssy Alexandra Diaz, Daniel T Chang","doi":"10.1097/PPO.0000000000000730","DOIUrl":"10.1097/PPO.0000000000000730","url":null,"abstract":"<p><strong>Abstract: </strong>The oligometastatic disease state, defined as a cancer with 5 or fewer sites of metastasis, is a therapeutic opportunity to improve oncologic outcomes. Colorectal cancer (CRC) was among the first for which oligometastatic treatment was used in routine clinical practice, and recent studies have shown potential for improved overall survival with metastasis-directed therapies. As CRC is the third most common cause of cancer death in men and women, improving oncologic outcomes in this population is of paramount importance. The relatively recent identification of this treatment paradigm and paucity of high-quality data have led to heterogeneity in clinical practice. This review will explore perspectives of a panel of surgical and radiation oncologists for complex or controversial cases of metastatic CRC.</p>","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":"30 4","pages":"280-289"},"PeriodicalIF":2.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141751205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Local-Regional Therapy for Oligometastatic Colorectal Cancer. 治疗寡转移性结直肠癌的局部区域疗法
IF 2.6 4区 医学
Cancer journal Pub Date : 2024-07-01 DOI: 10.1097/PPO.0000000000000729
Sean R Miller, Daniel T Chang
{"title":"Local-Regional Therapy for Oligometastatic Colorectal Cancer.","authors":"Sean R Miller, Daniel T Chang","doi":"10.1097/PPO.0000000000000729","DOIUrl":"https://doi.org/10.1097/PPO.0000000000000729","url":null,"abstract":"<p><strong>Abstract: </strong>Colorectal cancer is one of the most common malignancies in the United States as well as a leading cause of cancer-related death. Upward of 30% of patients ultimately develop metastatic disease, most commonly to the liver and lung. Untreated, patients have poor survival. Historically, patients with oligometastatic disease were treated with resection leading to long-term survival; however, there are many patients who are not surgical candidates. Innovations in thermal ablation, hepatic artery infusions, chemoembolization and radioembolization, and stereotactic ablative radiation have led to an expansion of patients eligible for local therapy. This review examines the evidence behind each modality for the most common locations of oligometastatic colorectal cancer.</p>","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":"30 4","pages":"272-279"},"PeriodicalIF":2.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141751206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment of Locally Recurrent Rectal Cancer: A Review. 局部复发直肠癌的治疗：综述。
IF 2.6 4区 医学
Cancer journal Pub Date : 2024-07-01 DOI: 10.1097/PPO.0000000000000728
Samuel N Regan, Samantha Hendren, John C Krauss, Oxana V Crysler, Kyle C Cuneo
{"title":"Treatment of Locally Recurrent Rectal Cancer: A Review.","authors":"Samuel N Regan, Samantha Hendren, John C Krauss, Oxana V Crysler, Kyle C Cuneo","doi":"10.1097/PPO.0000000000000728","DOIUrl":"https://doi.org/10.1097/PPO.0000000000000728","url":null,"abstract":"<p><strong>Abstract: </strong>Up to 10% of patients with locally advanced rectal cancer will experience locoregional recurrence. In the setting of prior surgery and often radiation and chemotherapy, these represent uniquely challenging cases. When feasible, surgical resection offers the best chance for oncologic control yet risks significant morbidity. Studies have consistently indicated that a negative surgical resection margin is the strongest predictor of oncologic outcomes. Chemoradiation is often recommended to increase the chance of an R0 resection, and in cases of close/positive margins, intraoperative radiation/brachytherapy can be utilized. In patients who are not surgical candidates, radiation can provide symptomatic relief. Ongoing phase III trials are aiming to address questions regarding the role of reirradiation and induction multiagent chemotherapy regimens in this population.</p>","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":"30 4","pages":"264-271"},"PeriodicalIF":2.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141751148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic and Therapeutic Application of Fibroblast Activation Protein Inhibitors in Oncologic and Nononcologic Diseases. 成纤维细胞活化蛋白抑制剂在肿瘤和非肿瘤疾病中的诊断和治疗应用。
IF 2.2 4区 医学
Cancer journal Pub Date : 2024-05-01 DOI: 10.1097/PPO.0000000000000719
Mariko Nakayama, Thomas A Hope, Ali Salavati
{"title":"Diagnostic and Therapeutic Application of Fibroblast Activation Protein Inhibitors in Oncologic and Nononcologic Diseases.","authors":"Mariko Nakayama, Thomas A Hope, Ali Salavati","doi":"10.1097/PPO.0000000000000719","DOIUrl":"10.1097/PPO.0000000000000719","url":null,"abstract":"<p><strong>Abstract: </strong>Fibroblast activation protein inhibitor positron emission tomography (PET) has gained interest for its ability to demonstrate uptake in a diverse range of tumors. Its molecular target, fibroblast activation protein, is expressed in cancer-associated fibroblasts, a major cell type in tumor microenvironment that surrounds various types of cancers. Although existing literature on FAPI PET is largely from single-center studies and case reports, initial findings show promise for some cancer types demonstrating improved imaging when compared with the widely used 18F-fludeoxyglucose PET for oncologic imaging. As we expand our knowledge of the utility of FAPI PET, accurate understanding of noncancerous uptake seen on FAPI PET is crucial for accurate evaluation. In this review, we summarize potential diagnostic and therapeutic applications of radiolabeled FAP inhibitors in oncological and nononcological disease processes.</p>","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":"30 3","pages":"210-217"},"PeriodicalIF":2.2,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140955479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nuclear Medicine Cancer Care-Current Status and Future Directions for Radiopharmaceutical Diagnostics and Theranostics for Cancer. 核医学癌症护理--癌症放射性药物诊断和治疗的现状与未来方向。
IF 2.2 4区 医学
Cancer journal Pub Date : 2024-05-01 DOI: 10.1097/PPO.0000000000000721
Sophia R O'Brien, David A Mankoff
{"title":"Nuclear Medicine Cancer Care-Current Status and Future Directions for Radiopharmaceutical Diagnostics and Theranostics for Cancer.","authors":"Sophia R O'Brien, David A Mankoff","doi":"10.1097/PPO.0000000000000721","DOIUrl":"https://doi.org/10.1097/PPO.0000000000000721","url":null,"abstract":"","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":"30 3","pages":"140-141"},"PeriodicalIF":2.2,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140955660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Theranostics in Neuroendocrine Tumors. 神经内分泌肿瘤的血清疗法。
IF 2.2 4区 医学
Cancer journal Pub Date : 2024-05-01 DOI: 10.1097/PPO.0000000000000723
Nadine Mallak, Sophia R O'Brien, Daniel A Pryma, Erik Mittra
{"title":"Theranostics in Neuroendocrine Tumors.","authors":"Nadine Mallak, Sophia R O'Brien, Daniel A Pryma, Erik Mittra","doi":"10.1097/PPO.0000000000000723","DOIUrl":"https://doi.org/10.1097/PPO.0000000000000723","url":null,"abstract":"<p><strong>Abstract: </strong>Neuroendocrine tumors (NETs) are rare tumors that develop from cells of the neuroendocrine system and can originate in multiple organs and tissues such as the bowels, pancreas, adrenal glands, ganglia, thyroid, and lungs. This review will focus on gastroenteropancreatic NETs (more commonly called NETs) characterized by frequent somatostatin receptor (SSTR) overexpression and pheochromocytomas/paragangliomas (PPGLs), which typically overexpress norepinephrine transporter. Advancements in SSTR-targeted imaging and treatment have revolutionized the management of patients with NETs. This comprehensive review delves into the current practice, discussing the use of the various Food and Drug Administration-approved SSTR-agonist positron emission tomography tracers and the predictive imaging biomarkers, and elaborating on 177Lu-DOTATATE peptide receptor radionuclide therapy including the evolving areas of posttherapy imaging practices and peptide receptor radionuclide therapy retreatment. SSTR-targeted imaging and therapy can also be used in patients with PPGL; however, this patient population has demonstrated the best outcomes from norepinephrine transporter-targeted therapy with 131I-metaiodobenzylguanidine. Metaiodobenzylguanidine theranostics for PPGL will be discussed, noting that in 2024 it became commercially unavailable in the United States. Therefore, the use and reported success of SSTR theranostics for PPGL will also be explored.</p>","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":"30 3","pages":"185-193"},"PeriodicalIF":2.2,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140955974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PET Imaging of Metabolism, Perfusion, and Hypoxia: FDG and Beyond. 新陈代谢、灌注和缺氧的 PET 成像：FDG 及其他。
IF 2.6 4区 医学
Cancer journal Pub Date : 2024-05-01 DOI: 10.1097/PPO.0000000000000716
Austin R Pantel, Seong-Woo Bae, Elizabeth J Li, Sophia R O'Brien, H Charles Manning
{"title":"PET Imaging of Metabolism, Perfusion, and Hypoxia: FDG and Beyond.","authors":"Austin R Pantel, Seong-Woo Bae, Elizabeth J Li, Sophia R O'Brien, H Charles Manning","doi":"10.1097/PPO.0000000000000716","DOIUrl":"10.1097/PPO.0000000000000716","url":null,"abstract":"<p><strong>Abstract: </strong>Imaging glucose metabolism with [18F]fluorodeoxyglucose positron emission tomography has transformed the diagnostic and treatment algorithms of numerous malignancies in clinical practice. The cancer phenotype, though, extends beyond dysregulation of this single pathway. Reprogramming of other pathways of metabolism, as well as altered perfusion and hypoxia, also typifies malignancy. These features provide other opportunities for imaging that have been developed and advanced into humans. In this review, we discuss imaging metabolism, perfusion, and hypoxia in cancer, focusing on the underlying biology to provide context. We conclude by highlighting the ability to image multiple facets of biology to better characterize cancer and guide targeted treatment.</p>","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":"30 3","pages":"159-169"},"PeriodicalIF":2.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11101148/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140955787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiopharmaceuticals for Cancer Diagnosis and Therapy: New Targets, New Therapies-Alpha-Emitters, Novel Targets. 用于癌症诊断和治疗的放射性药物：新靶点、新疗法--α-发射体、新靶点。
IF 2.6 4区 医学
Cancer journal Pub Date : 2024-05-01 DOI: 10.1097/PPO.0000000000000720
Neil K Taunk, Freddy E Escorcia, Jason S Lewis, Lisa Bodei
{"title":"Radiopharmaceuticals for Cancer Diagnosis and Therapy: New Targets, New Therapies-Alpha-Emitters, Novel Targets.","authors":"Neil K Taunk, Freddy E Escorcia, Jason S Lewis, Lisa Bodei","doi":"10.1097/PPO.0000000000000720","DOIUrl":"10.1097/PPO.0000000000000720","url":null,"abstract":"<p><strong>Abstract: </strong>Radiopharmaceutical therapy has emerged as a promising approach for the treatment of various cancers. The exploration of novel targets such as tumor-specific antigens, overexpressed receptors, and intracellular biomolecules using antibodies, peptides, or small molecules has expanded the scope of radiopharmaceutical therapy, enabling precise and effective cancer treatment for an increasing number of tumor types. Alpha emitters, characterized by their high linear energy transfer and short path length, offer unique advantages in targeted therapy due to their potent cytotoxicity against cancer cells while sparing healthy tissues. This article reviews recent advancements in identifying novel targets for radiopharmaceutical therapy and applications in utilizing α-emitters for targeted treatment.</p>","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":"30 3","pages":"218-223"},"PeriodicalIF":2.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11232930/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140955883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信